Relay shares had been under pressure since October when initial results from VIKTORIA-1’s wild-type cohort exceeded market ...
Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, ...
Relay Therapeutics’ Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results